EPHA2 and breast cancer: For example, we previously demonstrated that synthetic EphA2-targeting agonistic agents conjugated with gemcitabine or paclitaxel had superior efficacy compared to gemcitabine or paclitaxel alone in mouse models of pancreatic cancer [22] and breast cancer, respectively [31].